Current approved medical therapies for endometriosis rely on drugs that suppress ovarian steroids and induce a hypoestrogenic state, which determines the atrophy of the ectopic endometrium. Gonadotropin-releasing hormone analogs such as danazol, progestogens and estrogen-progestin combinations have all proven effective in relieving pain and reducing the extent of endometriotic implants. However, symptoms often recur after discontinuation of therapy and hypoestrogenism-related side effects limit the long-term use of most medications. Recently, knowledge of the pathogenesis of endometriosis, particularly at the molecular level, has grown substantially, providing a rational basis for the development of new drugs with precise targets that may be safely administered over the long term.
|Titolo:||Medical management of endometriosis|
|Parole Chiave:||Amenorrhea; Dysmenorrhea; Dyspareunia; Endometriosis; Hormonal treatment; Medical treatment; Pelvic pain|
|Settore Scientifico Disciplinare:||Settore MED/40 - Ginecologia e Ostetricia|
|Data di pubblicazione:||mar-2006|
|Digital Object Identifier (DOI):||10.2217/17455057.2.2.297|
|Appare nelle tipologie:||01 - Articolo su periodico|